Week in Review: BeiGene Raises $97 Million for Cancer Drugs

BeiGene of Beijing completed a $97 million funding to advance its portfolio of targeted cancer drugs and immuno-oncology therapies; JHL Biotech, a Taiwan-China biopharma, closed a Series C round of $45.6 million, the last funding before its IPO in Taiwan; Hutchison MediPharma will receive $18 million in milestones as part of Lilly's in-licensing of a novel VEGF inhibitor; Harbin Gloria Pharma in-licensed China rights to a novel anti-constipation drug from Sucampo of the US; WuXi PharmaTech reported 2015 Q1 earnings grew 23% from the year earlier to $180 million, though GAAP net income was flat at $18 million; SciClone Pharma reported first quarter revenues rose 26% and net income doubled; Neusoft Medical Systems of China launched its latest high-end CT scanner, the NeuViz 128 CT, in global markets; and Luye Pharma completed three US clinical studies of its investigational version of risperidone, an anti-psychotic. More details.... Stock Symbols: (NYSE: LLY) (SHE: 2437) (NSDQ: SCMP) (NYSE: WX) (NSDQ: SCLN) (SHA: 600718) (HK: 2186) Share this with colleagues: // //